logo
logo

Micreos Secures €32 Million For Its Endolysin-Based Platform As Sustainable Alternative To Antibiotics

Micreos Secures €32 Million For Its Endolysin-Based Platform As Sustainable Alternative To Antibiotics

09/30/21, 9:30 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/NL.svgthe hague
Money raised
€32 million
Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Company Info

Company
Micreos.
Location
the hague, south holland, netherlands
Additional Info
Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications, The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, Micreos has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people. SOURCE Micreos